View Item 

Show simple item record

CheckMate 141: 1‐Year Update and Subgroup Analysis of Nivolumab as First‐Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer
dc.contributor.authorGillison, Maura L.
dc.contributor.authorBlumenschein, George
dc.contributor.authorFayette, Jerome
dc.contributor.authorGuigay, Joel
dc.contributor.authorColevas, A. Dimitrios
dc.contributor.authorLicitra, Lisa
dc.contributor.authorHarrington, Kevin J.
dc.contributor.authorKasper, Stefan
dc.contributor.authorVokes, Everett E.
dc.contributor.authorEven, Caroline
dc.contributor.authorWorden, Francis
dc.contributor.authorSaba, Nabil F.
dc.contributor.authorIglesias Docampo, Lara Carmen
dc.contributor.authorHaddad, Robert
dc.contributor.authorRordorf, Tamara
dc.contributor.authorKiyota, Naomi
dc.contributor.authorTahara, Makoto
dc.contributor.authorMonga, Manish
dc.contributor.authorLynch, Mark
dc.contributor.authorLi, Li
dc.contributor.authorFerris, Robert L.
dc.date.accessioned2018-11-20T15:35:56Z
dc.date.available2019-11-01T15:10:33Zen
dc.date.issued2018-09
dc.identifier.citationGillison, Maura L.; Blumenschein, George; Fayette, Jerome; Guigay, Joel; Colevas, A. Dimitrios; Licitra, Lisa; Harrington, Kevin J.; Kasper, Stefan; Vokes, Everett E.; Even, Caroline; Worden, Francis; Saba, Nabil F.; Iglesias Docampo, Lara Carmen; Haddad, Robert; Rordorf, Tamara; Kiyota, Naomi; Tahara, Makoto; Monga, Manish; Lynch, Mark; Li, Li; Ferris, Robert L. (2018). "CheckMate 141: 1‐Year Update and Subgroup Analysis of Nivolumab as First‐Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer." The Oncologist 23(9): 1079-1082.
dc.identifier.issn1083-7159
dc.identifier.issn1549-490X
dc.identifier.urihttps://hdl.handle.net/2027.42/146487
dc.description.abstractNivolumab significantly improved overall survival (OS) vs investigator’s choice (IC) of chemotherapy at the primary analysis of randomized, open‐label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow‐up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first‐line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.Results of the CheckMate 141 trial are reported, highlighting outcomes among patients who received nivolumab compared with investigator’s choice of therapy as first‐line treatment for patients with recurrent or metastatic squamous cell carcinoma of the head and neck after progressing on platinum therapy for locally advanced disease.
dc.publisherWiley Periodicals, Inc.
dc.titleCheckMate 141: 1‐Year Update and Subgroup Analysis of Nivolumab as First‐Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146487/1/onco12455-sup-0001-Figure01.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146487/2/onco12455.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146487/3/onco12455_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146487/4/onco12455-sup-0002-Tables01.pdf
dc.identifier.doi10.1634/theoncologist.2017-0674
dc.identifier.sourceThe Oncologist
dc.identifier.citedreferenceZenda S, Onozawa Y, Boku N et al. Single‐agent docetaxel in patients with platinum‐refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN). Jpn J Clin Oncol 2007; 37: 477 – 481.
dc.identifier.citedreferenceMachiels JP, Subramanian S, Ruzsa A et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous‐cell carcinoma of the head and neck after failure of platinum‐based chemotherapy: An open‐label, randomised phase 3 trial. Lancet Oncol 2011; 12: 333 – 343.
dc.identifier.citedreferenceNational Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Head and Neck Cancers. Available at https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed May 8, 2017.
dc.identifier.citedreferenceArgiris A, Gillison M, Ferris RL et al. A randomized, open‐label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first‐line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck‐CheckMate 651. Ann Oncol 2016; 27 ( suppl 6 ): 1016TiPa.
dc.identifier.citedreferenceHaddad R, Gillison M, Ferris RL et al. Double‐blind, two‐arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi‐placebo (PBO) as first‐line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714. Ann Oncol 2016; 27 ( suppl 6 ): 1017TiPa.
dc.identifier.citedreferenceHarrington KJ, Ferris RL, Blumenschein G Jr et al. Nivolumab versus standard, single‐agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): Health‐related quality‐of‐life results from a randomised, phase 3 trial. Lancet Oncol 2017; 18: 1104 – 1115.
dc.identifier.citedreferenceVermorken JB, Mesia R, Rivera F et al. Platinum‐based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116 – 1127.
dc.identifier.citedreferenceFerris RL, Blumenschein G Jr, Fayette J et al. Nivolumab for recurrent squamous‐cell carcinoma of the head and neck. N Engl J Med 2016; 375: 1856 – 1867.
dc.identifier.citedreferenceNguyen‐Tan PF, Zhang Q, Ang KK et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: Long‐term report of efficacy and toxicity. J Clin Oncol 2014; 32: 3858 – 3866.
dc.identifier.citedreferencede Andrade DA, Machiels JP. Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum‐based chemotherapy. Curr Opin Oncol 2012; 24: 211 – 217.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
onco12455-sup-0001-Figure01.pdf
Size:
364.1KB
Format:
PDF
View/Open
Name:
onco12455.pdf
Size:
611.0KB
Format:
PDF
View/Open
Name:
onco12455_am.pdf
Size:
822.7KB
Format:
PDF
View/Open
Name:
onco12455-sup-0002-Tables01.pdf
Size:
188.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.